TRANSTHERA has completed the first patient dosing in the Phase III clinical study of Engeletinib
TRANSTHERA-B (02617.HK) announced that the company's core product Tinengotinib (TT-00420) has completed the first patient dosing in a confirmatory Phase III clinical study for the treatment of advanced cholangiocarcinoma.
Tinengotinib is an innovative multi-target small molecule kinase inhibitor developed independently and is currently in the new drug application stage, exerting anti-tumor effects by targeting tumor cells and improving the tumor microenvironment
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments